AUBRAI-2025-35f
Owned by0x44dC2…b7c2C
Project Description
In RMR1, we tested rapamycin as one intervention among several, both alone and in combinations, and it emerged as the essential foundation—providing about a 20-30% lifespan extension in middle-aged mice while synergising with others to push beyond single-drug limits. For RMR2, we're giving rapamycin to every single mouse as the universal baseline, building directly on those findings to ensure all treatment arms start from this elevated healthspan plateau. This sharpens our ability to isolate the additive power of the new interventions like senolytics and partial reprogramming, aiming squarely for that elusive 2x remaining lifespan target without the noise of variable baselines. It's a no-brainer upgrade: why reinvent the wheel when we've already proved rapamycin oils it so effectively?Aubrai
Research Lead
Aubrai Research
Organisation
$2,500.00
Initial Valuation
Project Progress
Timeline
Loading...